StockData
Biodexa Pharmaceuticals Plc logo

Biodexa Pharmaceuticals Plc (BDRX) stock

BDRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 27, 2026Score 1/30
$2.14−0.10 (-4.46%)

Close on Nov 17, 2026Market cap $4.83MP/E –Yield –

Biodexa Pharmaceuticals enterprise value

Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.

Biodexa Pharmaceuticals's enterprise value was -$3.00M on Nov 11, 2026, against $3.63M a year earlier. Over the last 5 years it ranged from -$9.48M to $59.17B, with a median of $5.52M.

Enterprise Value at the end of each year

PeriodPeriod endValueChange
2026Nov 11, 2026-$3.00M–
2025Dec 31, 2025-$930.08K–
2024Dec 31, 2024-$952.17K–
2023Dec 29, 2023-$4.64M-100.0%
2022Dec 30, 2022$10.61B-82.1%
2021Dec 31, 2021$59.17B+22011.7%
2020Dec 31, 2020$267.60M+223.1%
2019Dec 31, 2019$82.82M-45.0%
2018Dec 31, 2018$150.59M-74.2%
2017Dec 29, 2017$583.32M-62.1%
2016Dec 30, 2016$1.54B–

More Biodexa Pharmaceuticals figures

See a number that looks wrong?